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Abstract
Inspiratory muscle weakness in patients with COPD is of major clinical relevance. For instance,
maximum inspiratory pressure generation is an independent determinant of survival in severe
COPD. Traditionally, inspiratory muscle weakness has been ascribed to hyperinflation-induced
diaphragm shortening. However, more recently, invasive evaluation of diaphragm contractile
function, structure, and biochemistry demonstrated that cellular and molecular alterations occur,
of which several can be considered pathologic of nature. Whereas the fiber type shift towards
oxidative type I fibers in COPD diaphragm is regarded beneficial, rendering the overloaded
diaphragm more resistant to fatigue, the reduction of diaphragm fiber force generation in vitro likely
contributes to diaphragm weakness. The reduced diaphragm force generation at single fiber level
is associated with loss of myosin content in these fibers. Moreover, the diaphragm in COPD is
exposed to oxidative stress and sarcomeric injury. This review postulates that the oxidative stress
and sarcomeric injury activate proteolytic machinery, leading to contractile protein wasting and,
consequently, loss of force generating capacity of diaphragm fibers in patients with COPD.
Interestingly, several of these presumed pathologic alterations are already present early in the
course of the disease (GOLD I/II), although these patients appear not limited in their daily life
activities. Treatment of diaphragm dysfunction in COPD is complex since its etiology is unclear, but
recent findings indicate the ubiquitin-proteasome pathway as a prime target to attenuate diaphragm
wasting in COPD.
Introduction
Chronic obstructive pulmonary disease (COPD) has been
predicted to become the third leading cause of death and
the fifth commonest cause of disability in the world by
2020 [1]. Today it is recognized that COPD affects func-
tion of other organs besides the lungs. In particular, dys-
function of the respiratory muscles has been shown to
occur in patients with COPD. Dyspnea is the most disa-
bling symptom in patients with COPD, and could result
from a decreased capacity of the respiratory muscles to
meet an increased mechanical load. Hypercapnic respira-
tory failure due to inspiratory muscle weakness [2] is asso-
ciated with morbidity in these patients [3], and maximum
inspiratory pressure is an independent determinant of sur-
vival in these patients [4]. These studies stress the impor-
tance of inspiratory muscle dysfunction in patients with
COPD. Accordingly, the interest in defining the underly-
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ing causes of inspiratory muscle weakness in COPD has
increased over the recent years.
The majority of studies dealing with factors contributing
to inspiratory muscle weakness in COPD has focused on
the diaphragm, mainly because the diaphragm is the prin-
ciple muscle of inspiration. Patients with COPD have a
lower transdiaphragmatic pressure generating capacity
than healthy subjects [5], which has been ascribed to
hyperinflation-induced diaphragm shortening, placing
the diaphragm at a mechanical disadvantage [6]. When
compensated for reduced muscle length, diaphragm func-
tion was suggested to be preserved or even improved in
severe COPD [7]. However, the invasive evaluation of the
human diaphragm has accelerated the understanding of
the pathogenesis of diaphragm weakness in COPD. Since
the late nineties an increasing number of papers has been
published describing altered functional, structural and
metabolic characteristics in diaphragm biopsies of
patients with COPD [8-21]. Importantly, several of these
changes occur already early in the course of the disease
[11,12,18,19,21] and show a strong negative correlation
with respiratory muscle strength [14,17]. Together these
findings point towards a new concept in which the patho-
genesis of inspiratory muscle dysfunction in COPD is
related to cellular and molecular changes within the dia-
phragm, and occurs much earlier as previously assumed.
The aim of the present paper is to review the current
knowledge on the effect of COPD on the human dia-
phragm, and to generate a hypothesis for further research.
First, diaphragm performance in vivo will be discussed
briefly. Second, studies describing changes in the dia-
phragm will be reviewed. Finally, potential causes for the
observed cellular and molecular changes in COPD dia-
phragm will be addressed.
Diaphragm performance in COPD: in vivo studies
Diaphragm performance is mainly characterized by its
strength and endurance. Strength is defined as the capac-
ity of the muscle to generate force and endurance is
defined as the capacity of the muscle to maintain a certain
force over time, in other words, to resist fatigue. Loss in
either strength or endurance results in diaphragm weak-
ness and impaired performance.
Force generation of the diaphragm in vivo is determined
by central drive, phrenic nerve conductance, neuromuscu-
lar transmission and excitation-contraction coupling.
Direct determination of diaphragm muscle force generat-
ing capacity in vivo is not possible. Instead the capacity of
the inspiratory muscles to generate negative intrathoracic
or transdiaphragmatic pressure is usually determined, and
used as a measure for respiratory muscle strength. How-
ever, it should be emphasized that these methods do not
solely depend on muscle function, but on motivation,
central drive and nerve function as well.
It has been consistently demonstrated that patients with
severe COPD generate less maximal inspiratory pressure
and transdiaphragmatic pressure by voluntary manoeu-
vres, but also by phrenic nerve stimulation (ruling out
effects of central drive), compared to patients without
COPD [5,7,22-24]. Therefore, strength is regarded as a
limiting factor in diaphragm performance in COPD.
Indeed, inspiratory muscle weakness was shown to be
related to dyspnea [25], and maximal inspiratory pressure
is an independent determinant of survival in COPD [4].
Previous work by Similowski and co-workers [7] sug-
gested that weakness of the diaphragm could be explained
by hyperinflation-induced diaphragm shortening, which
places the diaphragm on a suboptimal position on its
force-length relationship. They revealed that at equivalent
lung volumes, the generated transdiaphragmatic pressures
were even higher in some patients with COPD compared
to healthy subjects. However, in addition to a mechanical
explanation for diaphragm weakness in COPD, several
studies proposed structural adaptations in the diaphragm
to be at play. For instance, parallel reductions of inspira-
tory and expiratory pressures are described in moderate-
to-severe COPD patients [26,27]. Since the expiratory
muscles are not at a mechanical disadvantage, these find-
ings suggest that some COPD patients have generalized
diaphragm weakness. This notion is supported by the
high correlation between maximal inspiratory and expira-
tory pressures in their COPD patients [26].
The present data dealing with diaphragm endurance in
COPD are limited, mainly because endurance tests are dif-
ficult to perform and interpret (for instance, diaphragm
endurance tests imply normalized patient stimulation
and a high degree of patient motivation). Newell et al. [5]
tested diaphragm endurance by measuring pressure out-
put during repeated maximal voluntary contractions of
the inspiratory muscles. During the endurance sequence
the decline in pressure was less in patients with severe
COPD compared to individuals with normal lung func-
tion. Later, these findings were confirmed by other studies
in patients with moderate-to-severe COPD [28,29]. So,
despite the greater load and recruitment, diaphragm
endurance appears to be increased in COPD. This is at
least partly accounted for by diaphragm remodelling
[15,16] and a shorter respiratory duty cycle [30]. For a
review on this topic see Laghi and Tobin [6].
Cellular and molecular changes in the diaphragm in COPD
In the last decade, several studies were published investi-
gating diaphragm biopsies from both patients with and
without COPD. The obtained diaphragm specimens
allowed the evaluation of functional, structural and meta-Respiratory Research 2008, 9:12 http://respiratory-research.com/content/9/1/12
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bolic changes in diaphragm fibers of COPD patients.
These studies improved the understanding of the effects of
COPD on respiratory muscle performance.
Diaphragm fiber type distribution
A consistent alteration in the diaphragm of COPD
patients is a fiber type shift towards more oxidative, type
I, fibers.
Fiber typing can be performed histochemically by staining
myofibrillar ATPase (type I, IIa, and IIx) [31] or by deter-
mination of mitochondrial enzyme activity (slow-twitch
oxidative, fast-twitch oxidative-glycolytic, and fast-twith
glycolytic) [32]. More recently, myofibrillar ATPase stain-
ing was shown to correspond to the expression of differ-
ent myosin heavy chain isoforms (MHCslow, MHC2A,
MHC2B and MHC2X), that can be identified by immunore-
activity to specific antibodies and/or by protein electro-
phoresis [33]. Type I fibers have a slow twitch, and
depend mainly on aerobic metabolism and are therefore
fatigue resistant. In contrast, type IIx fibers have a fast
twitch and their metabolism is anaerobic glycolytic,
which renders them susceptible for fatigue. Type IIa fibers
have intermediate properties; they do have a fast twitch
but are capable of working under both aerobic and anaer-
obic conditions and are therefore relatively fatigue-resist-
ant. Maximal tension development of mammalian muscle
is dependent on fiber type, with the lowest tension devel-
oped by type I fibers and the highest tension by type IIx
fibers. However, in humans this fiber type-dependency of
tension generating capacity is less obvious (for review see
Bottinelli and Reggiani [34]).
The human diaphragm is chronically active and is among
the most aerobicaly adapted striated muscles. Indeed, in
individuals with normal lung function the diaphragm
consists of a relatively high proportion (~50%) of type I
fibers, compared to type IIa (~30%) and IIx (~20%) fibers
[15,35,36]. In patients with COPD, the diaphragm works
against an increased work load due to airflow limitation
and geometrical changes in the thorax as a result of pul-
monary hyperinflation. It has been hypothesized that the
increased workload emulates endurance training of the
diaphragm in these patients. In line with this, Levine and
coworkers found an increased proportion of type I fibers
in the diaphragm of patients with severe COPD, whereas
the proportion of fast, fatiguing fibers (type II) was
decreased [15] (figure 1). These findings were confirmed
by other studies in patients with severe [13,17,35,37-39],
but also mild-to-moderate COPD [19,21]. Several studies
have shown that other inspiratory muscles, such as the
external intercostal muscles, do not exhibit a fiber type
shift in either direction in patients with moderate [40]
and severe COPD [38]. The shift from type II towards type
I fibers is regarded as beneficial as it may render the COPD
diaphragm more resistant to fatigue [15].
Besides a shift towards type-I fibers, the diaphragm in
severe COPD is characterized by a fast-to-slow shift of the
sarcoplasmic reticulum calcium-ATPase (SERCA), as
shown by Nguyen et al. [39]. In addition, the content of
the fast SERCA-isoform was decreased. SERCAs pump cal-
cium from the myoplasm into the sarcoplasmic reticulum
and thereby initiate striated muscle relaxation. Although
not studied, reduced SERCA pumping and the resulting
slower relaxation could affect the force-frequency charac-
teristics of diaphragm fibers in COPD. First, for a given
level of force generation a lower stimulation frequency is
needed. Second, lower stimulation frequencies will
reduce the energetic cost of calcium pumping in COPD
diaphragm fibers and thereby increase efficiency.
Diaphragm metabolism
Force generation by striated muscle is powered by adeno-
sine triphosphate (ATP), a 'high energy' compound. Curi-
ously, for such an important substance as ATP, it is found
in relatively low concentrations within cells. Striated mus-
cle, and especially the diaphragm with its high duty cycle,
has a high metabolic rate and would use up the available
ATP in a few seconds if it was not rapidly regenerated. ATP
generation in striated muscle occurs via aerobic and
anaerobic enzymatic pathways. In vitro determination of
Myosin heavy chain isoform distribution, analyzed by western  blot, in the costal diaphragm from severe COPD and non- COPD patients Figure 1
Myosin heavy chain isoform distribution, analyzed by western 
blot, in the costal diaphragm from severe COPD and non-
COPD patients. Diaphragm from COPD patients contains a 
higher proportion of slow myosin heavy chain isoform and 
lower proportions of IIA and IIX isoforms compared to the 
diaphragm from non-COPD patients. Reproduced from Lev-
ine et al. [15] with permission.Respiratory Research 2008, 9:12 http://respiratory-research.com/content/9/1/12
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enzyme activities involved in muscle metabolism pro-
vides information regarding changes in expression of pro-
teins involved in these metabolic pathways. Typical
anaerobic enzymes are phophorylase, hexokinase and lac-
tate dehydrogenase (LDH), which are mainly present in
the cytosol. Typical aerobic enzymes are succinic dehydro-
genase (SDH) citrate synthase (CS) and L(+)3-hydroacyl-
CoA-dehydrogenase (HADH), which are mainly
mitochondria-associated.
As mentioned previously, the different fiber types have
distinct metabolic properties. Therefore, the shift towards
type I fibers in COPD diaphragm is expected to result in
an increased oxidative capacity. Indeed, it is well estab-
lished that the activity of oxidative enzymes is increased in
COPD diaphragm, with a concomitant decrease in glyco-
lytic enzyme activities.
Several labs have reported increased activity of the oxida-
tive enzymes CS, SDH and HADH in the diaphragm of
patients with COPD [13,19,41], whereas the activities of
the glycolytic enzymes hexokinase and LDH were
decreased [42]. Similar to the fiber type shift, the changes
in enzyme activities were present in some patients with
only moderate COPD [19,42]. In addition to changes in
enzyme activities, the mitochondrial oxidative capacity
relative to ATP demand appears increased in the dia-
phragm of patients with severe COPD [13]. Also,
enhanced function of the mitochondrial electron trans-
port chain in the diaphragm of severe COPD patients has
been reported [38]. Increased maximal mitochondrial res-
piration, and improved coupling of oxidation to phos-
phorylation was found in COPD diaphragm. In addition,
these changes were associated with increase of CS activity.
It was proposed that the increased mitochondrial effi-
ciency in ATP production was the result of changed per-
meability of the inner mitochondrial membrane, thereby
decreasing proton leak and basal respiration [38]. In
patients with moderate COPD no changes in diaphragm
mitochondrial efficiency were found [41] compared to
healthy subjects.
Together these data indicate that the changes in oxidative
capacity and mitochondrial function in the diaphragm
occur in line with the progression of COPD and the con-
comitant shift towards more oxidative type I fibers. In
other respiratory muscles, such as the external intercos-
tals, the increase in oxidative capacity associated with
COPD, appears to be less pronounced [38]. This was, at
least in part, explained by the absence of a fiber type shift
in these muscles.
Functional changes: diaphragm single fiber studies
Single fiber contractile properties
Recent data from Levine and co-workers [14], and our
group [18], indicate impaired contractile protein function
in diaphragm fibers from patients with COPD. These
studies evaluated the contractility of permeabilized
(skinned) single fibers dissected from diaphragm biopsies
obtained during thoracotomy. These biopsies do not
allow dissection of muscle fibers from tendon to tendon.
Thus fiber ends are not sealed, which disrupts normal
excitation-contraction coupling. However, the skinned
fiber model provides an excellent model for direct evalua-
tion of contractile protein function in these fibers. In
skinned fibers, the membranous structures, such as the
sarcolemma, sarcoplasmic reticulum and mitochondria,
are made highly permeable. This procedure leaves the
contractile proteins intact. Therefore, a skinned fiber can
be regarded as a collection of functionally isolated sar-
comeres in series and in parallel. Mounting of skinned fib-
ers between a force transducer and a length motor and
subsequent exposure of the fiber to calcium enables eval-
uation of contractile protein function. Recent data from
our lab [18] showed markedly reduced maximum force
generation of diaphragm fibers from patients with only
mild-to-moderate COPD compared to non-COPD
patients. (figure 2) The maximum force generated by a
muscle fiber is strongly dependent on the content of
myosin, the main contractile protein (figure 3). The
reduction of maximum force generated by COPD dia-
phragm fibers, as observed in our study, was associated
with loss of myosin content in these fibers [18]. On the
basis of their single fiber data, Levine et al. [15] calculated
that patients with severe COPD would generate only 60%
Maximum force generation of skinned diaphragm fibers from  non-COPD and mild-to-moderate COPD patients Figure 2
Maximum force generation of skinned diaphragm fibers from 
non-COPD and mild-to-moderate COPD patients. Maximum 
force, normalized to cross sectional area, of single fibers 
from COPD patients was lower in type slow and 2A fibers 
compared to non-COPD patients. Data are presented as 
model estimates ± sem. *: P < 0.05 different from non-
COPD group. Reproduced from Ottenheijm et al. [18] with 
permission.Respiratory Research 2008, 9:12 http://respiratory-research.com/content/9/1/12
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of the average maximal transdiaphragmatic specific force
compared to individuals with normal lung function.
Because maximal transdiaphragmatic pressures of severe
COPD patients are reduced to approximately 65% of con-
trol values [7,22-24], they proposed that changes at the
cellular and molecular level in the diaphragm of COPD
patients can fully account for the reduced diaphragm
strength in vivo in these patients [14].
It should be noted however, that in vivo the diaphragm
shortens against a submaximal load rather than that it per-
forms maximum isometric contractions. Thus, submaxi-
mal and kinetic parameters of muscle function provide
important physiological information. We found that at a
certain calcium concentration, the generated force relative
to maximum force, is less in fibers from COPD patients
compared to non-COPD patients [18]. In other words, the
calcium sensitivity of force generation is reduced. This
appears to be an important finding, as it could compro-
mise diaphragm function at submaximum activation in
vivo. Moreover, diaphragm fibers from COPD patients
had slower attachment/detachment rates of myosin to
Top: Simplified model of two muscle sarcomeres in parallel Figure 3
Top: Simplified model of two muscle sarcomeres in parallel. The sarcomere is comprised of the thin (mostly actin) filaments, 
the thick (mostly myosin) filaments, and the giant filamentous molecule titin. The thin filaments are anchored in the Z-line, 
where they are cross-linked by α-actinin. The thick filament is centrally located in the sarcomere and constitue the sarcomeric 
A-band. The myosin heads, or cross-bridges, on the thick filament interact with actin during activation. Titin spans the half-sar-
comeric distance from the Z-line to the M-line, thus forming a third sarcomeric filament. In the I-band region, titin is extensible 
and functions as a molecular spring that develops passive tension upon stretch. In the A-band titin is inextensible due to its 
strong interaction with the thick filament.Bottom: Electronmiscroscopic photograph of the ultrastructural organization of sar-
comeres in parallel.Respiratory Research 2008, 9:12 http://respiratory-research.com/content/9/1/12
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actin during activation [18]. These data show that, besides
loss of contractile protein in the diaphragm of patients
with mild-to-moderate COPD, the remaining contractile
proteins are dysfunctional. The molecular basis of this
protein dysfunction is unclear. However, probably
myosin and troponin are involved, as the functioning of
these proteins is an important determinant of myosin-
actin attachment/detachment rates and calcium sensitiv-
ity of force generation.
Single fiber passive properties
For optimal contractile function, besides contractile pro-
teins such as myosin, passive-elastic structures in the sar-
comere are needed [43]; deletion of these structures
abolishes both passive and active force generation by sin-
gle muscle fibers [43]. Therefore, in addition to active
force generation, passive force characteristics of muscle
fibers provide important information on muscle function.
Recently, we [21], and others [12], demonstrated that dia-
phragm fibers from patients with mild-to-moderate
COPD generate less passive tension upon fiber-stretch
compared to fibers from patients without COPD. Passive
tension in these fibers is mainly determined by the prop-
erties of titin [44,45]. Titin spans the half-sarcomeric dis-
tance from the Z-line to the M-line, thus forming a third
sarcomeric filament, apart from the thick (mostly myosin)
and thin (mostly actin) filaments [46]. In the I-band
region, titin is extensible (due to its elastic PEVK segment)
and functions as a molecular spring that develops passive
tension upon stretch. Titin gene transcript studies revealed
increased expression of exons coding for the spring ele-
ments in the elastic region of titin in COPD diaphragm
[21], most likely resulting in an elongated extensible titin
segment. (figure 4) These data strongly suggest that alter-
native splicing of the titin gene reduces the passive tension
generated by diaphragm fibers from COPD patients. In
contrast to myosin and nebulin content, titin content was
not reduced in the diaphragm of these patients. Appar-
ently, the diaphragm of patients with mild-to-moderate
COPD is subject to loss of specific proteins and qualitative
changes within molecules.
Diaphragm atrophy
Muscle atrophy is defined as the wasting or loss of muscle
tissue, resulting from an imbalance between protein syn-
thesis and degradation due to disease or deconditioning.
Atrophy is characterized by a decrease in protein content
and fiber cross sectional area resulting in reduced force
production. Diaphragm fiber atrophy is a consistent find-
ing in patients with severe COPD.
Both type I and type II diaphragm fibers show reduced
cross sectional area in patients with severe COPD com-
pared to non-COPD patients [15,47]. Another study in
severe COPD patients found reduced cross sectional area
in predominantly type I diaphragm fibers [13]. In contrast
to patients with severe COPD, reductions in diaphragm
fiber cross sectional area have not been found in mild or
moderate COPD patients [16,19,20,48,49]. Although
these data suggest that fiber atrophy occurs only in severe
COPD, measuring cross sectional area is not a very sensi-
tive method for detection of atrophy. Indeed, recent data
show contractile protein loss in the diaphragm in mild-to-
moderate COPD [11,18,21] (FEV1 ~70% predicted). In
these patients, the myosin content in both type I and IIa
diaphragm fibers was markedly reduced, while fiber cross
sectional area remained normal. Consequently, myosin
concentration was decreased in these fibers by ~50% [18].
As expected, this reduction in myosin content was associ-
ated with decreased maximum force generation in those
fibers, as discussed earlier.
In general, striated muscle atrophy results from increased
proteolysis, rather than decreased synthesis [50]. During
atrophy the bulk of myofibrillar protein degradation
occurs via the ubiquitin-proteasome pathway [51,52].
Proteolysis by the ubiquitin-proteasome pathway is
highly selective and precisely regulated [53]. Proteins
degraded via this pathway are labelled first with ubiquitin
through the action of specific ubiquitin ligases. In general,
only damaged or misfolded proteins are labelled. Ubiqui-
tin-conjugated proteins are subsequently recognized,
bound and degraded by the 20S proteasome [51]. Recent
work demonstrated activation of the ubiquitin-proteas-
ome pathway in the diaphragm of patients with mild-to-
moderate COPD, as indicated by increased proteasome
activity, elevated mRNA levels of the ubiquitin ligase
MAFbx [11], and elevated levels of ubiquitin-conjugated
proteins [18]. Moreover, unpublished data revealed that
inhibiting proteasome activity in vivo in an animal model
of COPD partially restored diaphragm myosin content
and force generation capacity [54]. These findings
strongly suggest a key role for ubiquitin-proteasome-
mediated muscle protein degradation in diaphragm weak-
ness in COPD. Activation of the endoprotease caspase-3 is
an initial step in myofilament proteolysis by cleavage of
myosin and actin [55]. In this way, activated caspase-3
yields fragments that are degradable by the ubiquitin-pro-
teasome pathway. Indeed, caspase-3 activity is increased
in the diaphragm of patients with mild-to-moderate
COPD compared to non-COPD patients [11].
Little is known regarding mediators that affect the rate of
muscle protein synthesis in COPD diaphragm, although
glycosaminoglycans might be involved. Glycosaminogly-
cans are linear unbranched polysaccharides, most of
which are covalently linked to a protein core to form pro-
teoglycans [56]. Depending on the nature of the gly-
cosaminoglycan-moiety, one can discern heparan sulfate,
dermatan sulfate, and chondroitin sulfate proteoglycans.Respiratory Research 2008, 9:12 http://respiratory-research.com/content/9/1/12
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A: Analysis of diaphragm transcripts of all titin's gene exons from mild-to-moderate COPD and non-COPD patients Figure 4
A: Analysis of diaphragm transcripts of all titin's gene exons from mild-to-moderate COPD and non-COPD patients. All exons 
listed are upregulated by at least 3-fold (P < 0.05) in diaphragm from COPD patients (black bars) when compared with dia-
phragm from non-COPD patients (white bars), and code for the extensible I-band segment of titin (i.e. PEVK segment). B: 
Immuno-fluorescence analysis of antibody ×156, directed against the titin domain encoded by exon 156, and antibody T12, 
directed against a titin domain near the sarcomeric Z-line. Double-staining with antibodies ×156 and T12 revealed increased 
staining intensity of ×156 in diaphragm cryosections from patients with COPD (green, A-B), whereas staining intensity of T12 
was comparable between both patient groups (red, C-D). Bar: 50 µm. Confocal microscopy demonstrated the expected stain-
ing pattern of both antibodies: red striation patterns of T12 indicating the location of the sarcomeric Z-lines and green stria-
tions of ×156 indicating the extensible titin regions of the sarcomere (E-F). Bar: 2.5 µm. Reproduced from Ottenheijm et al. 
[21] with permission.Respiratory Research 2008, 9:12 http://respiratory-research.com/content/9/1/12
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Most proteoglycans are found either on the cell surface, or
in the extracellular matrix [57,58]. In skeletal muscle gly-
cosaminoglycans are involved in numerous biological
processes, notably the orchestration of anabolic and cata-
bolic signaling by unique sulfation patterns on the
heparan sulfate molecule (for review see [59]). Heparan
sulfate is essential for the activation of individual mem-
bers of several growth factor families, including hepato-
cyte growth factor and insulin-like growth factor [60-65].
The dynamic spatiotemporal expression of proteoglycans
and heparan sulfate epitopes provides a micro-environ-
ment in which heparan sulfate mediates growth factor
activity by creating focal differences in concentration and
by facilitating ligand-receptor interactions [66]. Through
this modulating effect on growth factors, glycosaminogly-
cans are instrumental in skeletal muscle protein synthesis
and regeneration [67-69]. Recent work [10] indicates
down-regulation of a specific heparan sulfate epitope in
the diaphragm of patients with COPD. This down-regu-
lated heparan sulfate epitope appeared to be involved in
the binding of hepatocyte growth factor. As hepatocyte
growth factor is an important modulator of contractile
protein synthesis [70], its down-regulation may affect
contractile protein content in the diaphragm of patients
with COPD. Interestingly, these changes already occur in
patients with mild-to-moderate COPD (GOLD stage I/II).
It should be noted that the reduced diaphragm fiber cross
sectional area in severe COPD, besides compromising dia-
phragm force generation, could also represent a beneficial
adaptation by facilitating oxygen transport and diffusion
from the capillaries into the fibers to meet the increased
oxidative metabolism in COPD diaphragm (as discussed
earlier). However, previous studies reported comparable
capillarization between individuals with normal lung
function and mild-to-moderate [19] and moderate-to-
severe COPD patients [17], although diaphragmatic
mRNA levels of vascular endothelial growth factor are
increased in patients with moderate COPD [71], suggest-
ing enhanced angiogenesis.
Diaphragm injury
Striated muscle injury is characterized by morphological
abnormalities such as disruption of membranous struc-
tures (sarcolemma, mitochondria etc), degeneration of
the cytoplasm, and disorganization of the contractile
apparatus (including sarcomere disruption, Z-line stream-
ing and misalignment of the myofilaments). It is well
established that exertion can have profound effects on
striated muscle structure and can induce muscle injury.
For instance, injury of the diaphragm has been observed
in several animal models of respiratory loading [72,73].
Recent data clearly demonstrate increased diaphragm
injury in patients with COPD.
Increased sarcomere disruption has been found in the dia-
phragm of patients with moderate-to-severe COPD [8,20]
(figure 5). The FEV1 was inversely correlated with both sar-
comere disruption density and area fraction [20]. Data
from our group show Z-band streaming and accumula-
tions of Z-band material in the diaphragm, indicating
myofibrillar myopathy, in severe COPD [74]. In another
study in mild-to-moderate COPD patients (average FEV1,
60% predicted), diaphragm cross sections showed no
signs of injury, although sarcomere length appeared
shorter [16]. The latter was proposed to be the result of
hyperinflation-induced diaphragm shortening. Interest-
ingly, diaphragms from patients with moderate-to-severe
COPD were found to be three times more susceptible to
additional sarcomere disruption when breathing against
inspiratory loads compared to non-COPD patients [20].
In line with these findings, recent data from a post mortem
study in severe COPD patients reveal that acute-on-
chronic increase in ventilatory loading induced extensive
diaphragm injury and collagen accumulation [48].
Whereas intracellular, sarcomeric, injury in COPD dia-
phragm is evident, the membrane and the membrane-
associated proteins, which are essential for force transmis-
sion to adjacent fibers, appear intact [75]. Together, these
data indicate that sarcomeric injury is more pronounced
in COPD diaphragm and increases with progression of
the disease.
Electronmicroscopic photograph showing areas of normal  (A) and disrupted (B) sarcomeres in a diaphragm sample  from a patient with moderate-severe COPD Figure 5
Electronmicroscopic photograph showing areas of normal 
(A) and disrupted (B) sarcomeres in a diaphragm sample 
from a patient with moderate-severe COPD. Note the dis-
ruption and even absence of A- and I-bands. Reproduced 
from Orozco-levi et al. [20] with permission.Respiratory Research 2008, 9:12 http://respiratory-research.com/content/9/1/12
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In general, muscle injury is followed by an inflammatory
response and subsequent regeneration. However, previ-
ous studies found no evidence of inflammatory cells in
the diaphragm of patients with COPD, although injury
was evident, suggesting an altered response to injury
[8,20]. Muscle degeneration is followed by the activation
of a muscle repair or regeneration process in which satel-
lite cell activation is an important step [70]. Activated sat-
ellite cells proliferate and differentiate to new myofibers.
These newly formed fibers express embryonic/neonatal
forms of myosin heavy chain [70]. However, preliminary
data from our lab indicate that diaphragm satellite cell dif-
ferentiation into myotubes is impaired in COPD [76].
Also, Nguyen et al. [37] found lower expression of embry-
onic/neonatal myosin heavy chains in the diaphragm
from COPD patients compared to non-COPD patients,
and similar findings were reported in a preliminary study
from our lab [77]. Finally, in an animal model of COPD,
there was evidence of decreased MyoD and elevated
inhibitor of differentiation protein 2 (Id2) levels in dia-
phragm muscle [78], which may impair satellite cell dif-
ferentiation, and thus its regenerative capacity. Together,
these data suggest a non-adequate response to diaphragm
injury in patients with COPD.
Oxidative and nitrosative stress
Oxidative and nitrosative stress reflect an imbalance
between the production and scavenging of free radicals.
Free radicals are molecules with at least one unpaired elec-
tron in their outer orbital. Since electrons are usually more
stable when paired, radicals are more reactive than non-
radicals. In vivo, free radicals can be divided into oxygen-
and nitrogen-centred free radicals, such as superoxide
anion and nitric oxide, respectively. Sources for free radi-
cals in striated muscle include the mitochondrial electron
transport chain, xanthine oxidase, neutrophils and nitric
oxide synthases. Striated muscles generate free radicals at
rest and production increases during contractile activity
[79,80]. Their high reactivity makes it technically
extremely complex to measure free radical levels inside
muscle fibers. Therefore, in general, oxidative stress is
determined indirectly by measuring the levels of oxidized
proteins and/or lipids.
A recent study by Barreiro et al. [17] was the first to dem-
onstrate increased oxidative stress in the diaphragm of
patients with severe COPD. They reported higher protein
carbonyl groups and hydroxynonenal protein adducts,
both markers of protein oxidation. Importantly, the dia-
phragmatic levels of protein oxidation showed a strong
negative correlation with respiratory muscle strength. In
the diaphragm of moderate COPD patients no signs of
oxidative stress were present. In contrast to oxidative
stress, nitrosative stress was not elevated in COPD dia-
phragm [17]. This was supported by unchanged protein
tyrosine nitration levels in the diaphragm of these
patients.
Diaphragm versus peripheral muscles in COPD
One of the most remarkable alterations in COPD muscle
is the fiber type shift that occurs in opposite directions in
the diaphragm and peripheral muscles. Whereas the fiber
type shift in the diaphragm resembles that associated with
endurance training, adaptation of the limb muscles is
characterized by a shift towards more fatigable, glycolytic
type II fibers in severe COPD [81-84]. The changes in fiber
type composition of peripheral muscles in COPD corre-
late with the reduced activity of oxidative enzymes in
those muscles [85,86]. A study by Doucet et al. was the
first to investigate fiber type proportions in the diaphragm
and a limb muscle within the same patients with mild-to-
moderate COPD. They found a fiber type shift in the dia-
phragm, whereas a fiber type shift in limb muscles was
absent in these patients [19]. Apparently, fiber type shifts
in the diaphragm occur earlier in the disease process than
the changes in the limb muscles. In addition, several other
abnormalities associated with COPD are specific for
peripheral muscles or the diaphragm. For instance, in con-
trast to the diaphragm, peripheral muscles in COPD asso-
ciated with low body-mass-index show accelerated
apoptosis and inflammatory changes [87]. Also, whereas
diaphragm injury is a common feature in severe COPD,
profound peripheral muscle injury has not been reported.
On the other hand, atrophy appears to be a common fea-
ture in both the diaphragm and peripheral muscles of
COPD patients [81,88]. Also, similar to the diaphragm,
the peripheral muscles in COPD are exposed to oxidative
stress [89-92]. Nitrosative stress, however, appears to be
more specific to the peripheral muscles than the dia-
phragm, and was proposed to be the result of increased
activity of neuronal nitric oxide synthase in peripheral
muscles of COPD patients [92-94].
It should be noted that the concept of peripheral muscles
needs some differentiation. In general, the structure and
function of the upper limb muscles appears to be less
affected in COPD, presumably due to sustained activity
during daily activities, whereas muscles from the lower
limbs show more pronounced changes as a result of pro-
gressive deconditioning [95].
Genesis of a pathophysiological concept
The fiber type shift towards more oxidative type I fibers
may initially be regarded as beneficial as it renders the
overloaded COPD diaphragm more resistant to fatigue
[15]. In fact, contractile fatigue is an uncommon event
after exhaustive exercise in severe COPD [5,29,96]. How-
ever, the loss of myosin and force generating capacity in
diaphragm single fibers, and the increased sarcomericRespiratory Research 2008, 9:12 http://respiratory-research.com/content/9/1/12
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injury and oxidative stress, constitute maladaptive altera-
tions in the diaphragm of these patients [8,14,17,18,20],
and have been suggested to greatly impair diaphragm
function in vivo [14,17]. Together, these findings consti-
tute a cellular and molecular basis for the the notion that
strength and not fatigue is the main limiting factor for in
vivo respiratory muscle performance in COPD.
The strength of the diaphragm is strongly dependent on
its contractile protein content. Recent data suggest that
accelerated protein degradation via the ubiquitin-proteas-
ome pathway contributes to loss of myosin in COPD dia-
phragm, and constitutes an initial step in the pathogenesis
of diaphragm weakness in these patients. Chamberlain
[97] addressed the role of selective degradation of myosin
by the ubiquitin-proteasome pathway in cachexia [98].
Preferential loss of myosin would increase the average dis-
tance between myosin and actin filaments, inducing
reduction of fiber size later in the course of the disease to
restore filament lattice spacing needed for optimal con-
tractile function [97]. Indeed, loss of myosin precedes
reduction of fiber cross sectional area in COPD dia-
phragm [18]. Although speculative, these findings sup-
port the hypothesis that, in mild-to-moderate COPD, loss
of myosin is an initial, but functional important, step in
diaphragm muscle fiber atrophy, as observed in severe
COPD.
The giant protein titin might also be involved in dia-
phragm atrophy in COPD. The passive-elastic properties
of titin are essential for maintaining structural and
mechanical stability of the sarcomere during activation
[43,99]. However, recent studies indicate that titin is an
important player in the maintenance of striated muscle
mass as well [100]. Titin functions as a stretch sensor with
titin-based stiffness regulating muscle remodelling and
gene expression, through a signaling pathway linking
activity of titin's kinase domain to nuclear transcriptional
activity [100]. Reduced mechanical strain on the titin
kinase domain resulted in down-regulation of muscle-
specific gene transcription, and was suggested to cause
loss of contractile protein and muscle weakness in
patients with hereditary myopathy with early respiratory
failure [100]. We hypothesize that the reduced stiffness of
titin in the diaphragm of mild-to-moderate COPD
patients reduces its kinase domain activity, thereby induc-
ing loss of signaling between titin and the nucleus, result-
ing in decreased transcription of muscle-specific genes.
This could affect the production of contractile proteins,
and contribute to the loss of myosin in the diaphragm of
these patients, especially since diaphragm protein turno-
ver might be elevated.
The increased susceptibility of the COPD diaphragm to
inspiratory loading-induced sarcomeric injury appears to
be an important finding as it suggests that during exacer-
bations of COPD, when patients experience acute dia-
phragm loading, the diaphragm may develop additional
injury. This could compromise diaphragm strength even
more and consequently result in respiratory failure.
Indeed, COPD patients experiencing acute-on chronic res-
piratory loading have extensive diaphragm fiber injury
and fibrosis[48]. Moreover, the increased susceptibility to
injury implies that, although the sarcomeric ultrastructure
appears intact during electronmiscroscopical examina-
tion, the structural integrity of the sarcomere is, in fact,
weakened. Reduced stiffness of titin in COPD diaphragm
might play a role, as it could induce structural instability
of sarcomeres, leading to misalignment of myosin fila-
ments and inability of the muscle fiber to resist sarcomere
length inhomogeneity during activation. This overstretch-
ing of sarcomeres could contribute to the sarcomeric
injury observed in the diaphragm of patients with severe
COPD. In addition, the elevated levels of oxidized sarco-
meric proteins in the diaphragm of patients with severe
COPD might contribute to the increased susceptibility to
diaphragm injury. Oxidized proteins have impaired struc-
tural integrity and function, and are known substrates for
degradation via the ubiquitin-proteasome pathway [101].
These subtle structural modifications might be already
present in patients with mild-to-moderate COPD, and
play a role in the observed contractile protein dysfunction
and the pronounced loss of myosin by accelerating ubiq-
uitin-proteasome-mediated proteolysis. However, this is
not supported by previous findings in moderate COPD
patients, indicating similar levels of oxidized diaphragm
proteins compared to non-COPD patients [17]. The detec-
tion of oxidatively modified proteins is, however, depend-
ent on the sensitivity of the assays to measure such
damage [102]. Therefore, future studies using highly sen-
sitive proteomic analysis could resolve this issue. In
healthy striated muscle, upon injury a rapid and extensive
repair process is initiated to prevent loss of muscle mass.
The fact that COPD diaphragm displays impaired regener-
ative processes, although injury is evident, suggests that
impaired regeneration is involved in diaphragm atrophy.
The knowledge regarding diaphragm protein synthesis in
COPD is very limited. Therefore, a major challenge for
future studies will be to evaluate the relative contributions
of protein degradation and synthesis pathways to the loss
of contractile protein content in COPD diaphragm.
Identifying initial triggers leading to diaphragm weakness 
in COPD
Little is known regarding the etiology of cellular and
molecular changes in COPD diaphragm. Therefore, a
major challenge for future studies will be to identify the
triggers responsible for the observed changes in the COPD
diaphragm. This is especially challenging since severalRespiratory Research 2008, 9:12 http://respiratory-research.com/content/9/1/12
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adaptations are already present early in the course of the
disease. Mechanisms that might be involved include non-
systemic factors, such as increased diaphragm loading due
to pulmonary obstruction, and sytemic factors, such as
systemic inflammation. However, no studies have
reported systemic changes in patients with mild-to-mod-
erate COPD. Also, if a systemic etiology is proposed, alter-
ations in the diaphragm and peripheral muscles are
expected to share a high degree of similarity and, to a cer-
tain extent, develop simultaneously. However, the dia-
phragm and peripheral muscles appear differentially
affected in COPD, and the diaphragmatic alterations
appear to precede the peripheral muscle changes. There-
fore, at early onset of the disease, most likely other factors
are involved in the etiology of diaphragm weakness.
A potential trigger for the diaphragmatic changes in
COPD patients is elevated contractile activity of the dia-
phragm. Loaded breathing is known to impair diaphragm
contractility in healthy humans [103]. It was proposed
that free radicals were involved since treatment with N-
acteyl-cysteine, a molecule with antioxidant properties,
attenuated diaphragm dysfunction in these subjects [103].
In patients with severe COPD, diaphragm loading is
increased [104], and recent data suggest oxidative stress in
the diaphragm of these patients. Very little is known about
diaphragm loading in patients with only mild-to-moder-
ate COPD. Markers for oxidative stress were not elevated
in the diaphragm of these patients, but oxidative protein
modification could be too subtle for detection with the
applied assays. The fiber type shift towards type I fibers in
some patients with mild-to-moderate COPD does suggest
elevated contractile activity of the diaphragm in these
patients. With this in mind, we stress the importance of
future studies aimed at evaluating diaphragm contractile
activity in patients with mild or moderate COPD. The
obtained data should indicate whether or not increased
diaphragm loading might play a role in the development
of diaphragm weakness in COPD.
Cytokines promote striated muscle injury, impair contrac-
tile protein function [105] and stimulate proteolysis
through the ubiquitin-proteasome pathway in vitro [106-
108]. Circulating cytokines are proposed to initiate
cachexia-associated muscle wasting by selective targeting
myosin [97]. At rest, circulating levels of cytokines are ele-
vated in COPD, but only in a subgroup of severe COPD
patients [109-111]. However, physical exercise induces an
exaggerated systemic inflammatory and oxidative
response in patients with moderate COPD [112]. This
abnormal response could be harmful by inducing skeletal
and diaphragm muscle changes. It would be interesting to
know if this abnormal exercise-induced inflammatory
response is also present in patients with mild-to-moderate
COPD. In addition, the source for the exercise-induced
cytokines are yet to be determined. They have been attrib-
uted to bronchial inflammation, however, recent data
indicate differential regulation of the cytokine response in
induced sputum and plasma in COPD patients [113],
which may suggest additional origins for COPD-associ-
ated cytokinemia. The diaphragm provides an alternative
candiate. Diaphragm loading induces expression of
cytokines in rat diaphragm fibers [114] (for review see
Vasillakopoulos et al[115]). We speculate that the expres-
sion of cytokines is increased in the diaphragm of patients
with mild-to-moderate COPD, contributing to the
observed diaphragmatic changes by promoting sarcom-
eric injury, and protein modification and degradation.
Therefore, evaluation of the cytokine profile in the dia-
phragm of patients with mild or moderate COPD will
increase our understanding of the etiology of the cellular
and molecular changes in COPD diaphragm.
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